{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:30:13Z","timestamp":1789648213875,"version":"4.0.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/bor.0000000000000070","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T01:20:20Z","timestamp":1400548820000},"page":"371-376","source":"Crossref","is-referenced-by-count":20,"title":["Relevance of the gut\/joint axis for the management of spondyloarthritis in daily clinical practice"],"prefix":"10.1097","volume":"26","author":[{"given":"Heleen","family":"Cypers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Varkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis.","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy.","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis.","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.","volume":"45","author":"Cortes","year":"2013","journal-title":"Nature Genet"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"e01202","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.","volume":"2","author":"Scher","year":"2013","journal-title":"eLife"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","article-title":"The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.","volume":"180","author":"Taurog","year":"1994","journal-title":"J Exp Med"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/gut.52.3.370","article-title":"Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment.","volume":"52","author":"Dieleman","year":"2003","journal-title":"Gut"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing.","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/QCO.0b013e32832a8a5d","article-title":"Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases.","volume":"22","author":"Packey","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/ard.2004.028837","article-title":"CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohns disease.","volume":"64","author":"Laukens","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3899\/jrheum.100193","article-title":"Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial.","volume":"37","author":"Jenks","year":"2010","journal-title":"J Rheumatol"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.MIB.0000437495.30052.be","article-title":"Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohns disease, and pouchitis: meta-analysis of randomized controlled trials.","volume":"20","author":"Shen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.nut.2013.09.007","article-title":"Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis.","volume":"30","author":"Vaghef-Mehrabany","year":"2014","journal-title":"Nutrition"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model.","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.","volume":"58","author":"Van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.","volume":"58","author":"Van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2011-200859","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.","volume":"72","author":"Maksymowych","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis.","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease.","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/BOR.0b013e3283620177","article-title":"Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.","volume":"25","author":"Her","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00535-009-0102-2","article-title":"Present status and strategy of NSAIDs-induced small bowel injury.","volume":"44","author":"Higuchi","year":"2009","journal-title":"J Gastroenterol"},{"key":"R27-3-20210128","first-page":"226","article-title":"Do nonsteroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease Digest Dis S","volume":"55","author":"Feagins","year":"2010","journal-title":"ci"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective Cox-2 inhibitor in inflammatory bowel diseases.","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohns disease: current management.","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1586\/1744666X.2013.858859","article-title":"Certolizumab pegol in axial spondyloarthritis.","volume":"9","author":"Song","year":"2013","journal-title":"Exp Rev Clin Immunol"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","article-title":"Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.","volume":"141","author":"Kirkham","year":"2014","journal-title":"Immunology"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subdinical intestinal inflammation in ankylosing spondylitis.","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/gut.2006.115402","article-title":"The IL23 axis plays a key role in the pathogenesis of IBD.","volume":"56","author":"McGovern","year":"2007","journal-title":"Gut"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response.","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.37937","article-title":"In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis.","volume":"65","author":"Appel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis.","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Molec Immunol"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molimm.2013.07.013","article-title":"HLA-B27 misfolding and ankylosing spondylitis.","volume":"57","author":"Colbert","year":"2014","journal-title":"Molec Immunol"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial.","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohns disease.","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"R47-3-20210128","first-page":"S766","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).","volume":"65","author":"Poddubnyy","year":"2013","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T19:55:33Z","timestamp":1716753333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201407000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000070","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}